Teva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S. Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 mg-strength generic Erythromycin tablets, which are a therapeutic equivalent for the reference listed drug Erythromycin from Arbor Pharmaceuticals, according to […]
Business/Financial News
Most pharma executives see digital drug delivery as important, Molex says
A survey conducted by Molex and its Phillips-Medisize medical device delivery division highlights the importance of digitized drug delivery. Lisle, Ill.-based Molex and Phillips-Medisize commissioned Dimensional Research to poll 215 pharmaceutical professionals who are stakeholders in a range of digital drug delivery devices, according to a news release. Those devices are designed to provide a […]
Smiths Medical partners with Ivenix on infusion management suite
Smiths Medical announced today that it partnered with Ivenix on infusion management. Minneapolis-based Smiths Medical will invest an unspecified amount in the long-term partnership to “revolutionize” infusion management and improve patient safety while meeting the needs of healthcare providers, according to a news release. Boston-based Ivenix develops what it touts as “the first and only […]
Gyroscope Therapeutics launches IPO roadshow
Gyroscope Therapeutics announced today that it launched the roadshow for its initial public offering of nearly 7 million shares. London-based Gyroscope’s U.S. offering includes up to 6.75 million American Depository Shares (ADSs) representing 6.75 million ordinary shares, according to a news release. Gyroscope expects pricing for the IPO to range between $20 and $22 per […]
Bexson Biomedical wins U.S. patent for ketamine formulation
Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy. Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the […]
Dexcom dips after hours despite Street-beating Q1, raised guidance
Dexcom (NSDQ:DXCM) shares took a hit after hours today despite first-quarter results that beat the consensus forecast. DXCM shares were down -5.2% at $400 per share after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%. The San Diego-based glucose monitoring technology developer posted […]
West Pharmaceutical Services beats Street in Q1, raises guidance
West Pharmaceutical Services (NYSE:WST) posted Street-beating first-quarter financial results and raised its full-year guidance for 2021. The Exton, Pa.-based company posted profits of $151.2 million, or $1.99 per share, on sales of $670.7 million for the three months ended March 31, 2021, more than doubling its bottom-line on sales growth of 36.5%. Adjusted to exclude […]
Merck comes up short on Q1 forecast
Merck (NYSE:MRK) shares took a hit before hours today on first-quarter results that missed the consensus forecast. The Kenilworth, N.J.-based company posted profits of $3.2 billion, or $1.25 per share, on sales of $12.1 billion for the three months ended March 31, 2021, for a -1.2% bottom-line slide on revenues that remained almost identical year-over-year. […]
Teva Pharmaceuticals unchanged before hours on Q1 earnings beat
Teva Pharmaceuticals (NYSE:TEVA) shares stood firm before hours today on first-quarter earnings that topped the consensus forecast. The Tel Aviv, Israel-based company posted profits of $84 million, or 7¢ per share, on sales of $4 billion for the three months ended March 31, 2021, for a more-than tripled bottom-line despite a sales decline of -8.6%. […]
Valeo Pharma closes upsized $6.6M private placement
Valeo Pharma announced today that it closed an upsized private placement worth more than $6.6 million. Montreal, Canada-based Valeo issued 6,645 unsecured, non-convertible debenture units at a purchase price of $1,000 per unit, totaling gross proceeds of $6.645 million, according to a news release. Each debenture unit consists of one unsecured non-convertible debenture in the […]